Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the best confirmed response rate of daily
administration of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR and
VEGFR2) XL647 in subjects with NSCLC who have progressed after responding to treatment with
either erlotinib or gefitinib.